Guillermo Lay-Son

Dr. Guillermo Lay-Son

Pontificia Universidad Católica de Chile, Santiago, Región Metropolitana, Chile
+1
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
DMDianalee McKnight
Dianalee McKnight
AMAna Morales
Ana Morales
KHKathryn E. Hatchell
Kathryn E. Hatchell
SBSara L. Bristow
Sara L. Bristow
JBJoshua L. Bonkowsky
Joshua L. Bonkowsky
MPMariia Pavliuk
Mariia Pavliuk
Genetic etiologies are responsible for seizures in up to 40% of children and 23% of adults with epilepsy.1-7 Early use of genetic testing for diagnosis and clinical management has been proposed; however, recommendations for genetic testing in individuals with epilepsy are currently limited.8-11 Additionally, estimates of how often a molecular diagnosis has clinically actionable implications have varied widely, from 60% in a single-center study12 to 20% in a multicenter study,13 although more recent studies estimate 50%.6,14,15 Studies of treatment approaches based on genetic diagnoses have shown improved outcomes in patients with epilepsy.1,5,7,12,16-19

6 November 2014 in BMJ Open
Verified
Journal Article
Open access
PDF file
GRGabriela M Repetto
Gabriela M Repetto
MGM Luisa Guzmán
M Luisa Guzmán
IDIris Delgado
Iris Delgado
HLHugo Loyola
Hugo Loyola
MPMirta Palomares
Mirta Palomares
PAPatricia Alvarez
Patricia Alvarez
Objective Chromosome 22q11.2 deletion is the most commonly occurring known microdeletion syndrome. Deaths related to the syndrome have been reported, but the magnitude of death has not been quantified. This study evaluated the deletion's impact on survival and its clinical manifestations in a large cohort of Chilean patients. Design Demographic and clinical data of individuals with 22q11 deletions diagnosed between 1998 and 2013 were collected from medical records and death certificates. Case fatality rate was calculated and compared with national vital statistics. OR with 95% CI analysis was used to assess the association between clinical manifestations and death. Setting Genetic services in tertiary care centres in Chile, following patients with 22q11.2 deletion. Outcomes Fatality rate and associated factors. Results 59 of 419 patients (14.1%) died during the study period at a median of 3.4 months (range 0 to 32 years of age). Factors associated with death included congenital heart disease (OR 5.27; 95% CI 2.06 to 13.99; p<0.0001), hypocalcaemia (OR 4.27; 95% CI 1.67 to 11.15; p<0.002) and airway malacia (OR 13.37; 95% CI 1.19 to 110.51; p<0.002). Patients with deletions and defects such as tetralogy of Fallot with or without pulmonary atraesia, truncus arteriosus or ventricular septal defect, had a 2.6-fold to 4.6-fold higher death rate compared with nationwide reports for the same types of defects. Conclusions In this cohort, we observed a death rate of 14.1%, implying that one in seven patients with 22q11 deletion died during the study period. Significant associations with cardiac defects, hypocalcaemia and airway malacia were observed. Furthermore, the death risk in patients with 22q11 deletion and cardiac defects exceeded the global figures observed in Chile for infants with structurally similar but apparently isolated anomalies. These observations indicate a need to identify patients who may require specific perioperative management to improve survival.

1 April 2006 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
LSLilian Elena Jara Sosa
Lilian Elena Jara Sosa
SASandra Ampuero
Sandra Ampuero
ESEudocia Santibáñez
Eudocia Santibáñez
LSLorena Seccia
Lorena Seccia
JRJuan Rodríguez
Juan Rodríguez
JRJosé Miguel Reyes
José Miguel Reyes

11 May 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LLLuis E. León
Luis E. León
FBFelipe Benavides
Felipe Benavides
KEKarena Espinoza
Karena Espinoza
CVCecilia Vial
Cecilia Vial
PAPatricia Alvarez
Patricia Alvarez
GRGabriela M Repetto
Gabriela M Repetto
22q11.2 microdeletion syndrome (22q11.2DS) is the most common microdeletion disorder in humans, with an incidence of 1/4000 live births. It is caused by a heterozygous deletion of 1.5–3 Mb on chromosome region 22q11.2. Patients with the deletion present features that include neuropsychiatric problems, craniofacial abnormalities and cardiovascular malformations. However, the phenotype is highly variable and the factors related to the clinical heterogeneity are not fully understood. About 65% of patients with 22q11.2DS have congenital heart defects (CHD). The main goal of this study was to identify common CNVs in 22q11.2DS patients that could be associated with the incomplete penetrance of CHD. Analysis of genomic DNA from 253 patients with 22q11.2DS using array technology showed an association between a microduplication located in region 17q21.31 and CHD (p-value = 0.023, OR = 2.75, 95% CI = 1.17–7.03). This region includes the first three exons of KANSL1 gene. Bioinformatic analysis showed that KANSL1 and CRKL, a gene in the commonly deleted region of 22q11.2DS, are part of the same regulatory module in a miRNA-mRNA network. These results show that a KANSL1 microduplication, in combination with the 22q11.2 deletion, is associated with increased risk of CHD in these patients, suggesting that KANSL1 plays a role as a modifier gene in 22q11.2DS patients.

4 January 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
MPM. Cecilia Poli
M. Cecilia Poli
BRBoris Rebolledo-Jaramillo
Boris Rebolledo-Jaramillo
CLCatalina Lagos
Catalina Lagos
JOJoan Orellana
Joan Orellana
GMGabriela Moreno
Gabriela Moreno
GRGabriela M Repetto
Gabriela M Repetto
Rare diseases affect millions of people worldwide, and most have a genetic etiology. The incorporation of next-generation sequencing into clinical settings, particularly exome and genome sequencing, has resulted in an unprecedented improvement in diagnosis and discovery in the past decade. Nevertheless, these tools are unavailable in many countries, increasing health care gaps between high- and low-and-middle-income countries and prolonging the “diagnostic odyssey” for patients. To advance genomic diagnoses in a setting of limited genomic resources, we developed DECIPHERD, an undiagnosed diseases program in Chile. DECIPHERD was implemented in two phases: training and local development. The training phase relied on international collaboration with Baylor College of Medicine, and the local development was structured as a hybrid model, where clinical and bioinformatics analysis were performed in-house and sequencing outsourced abroad, due to lack of high-throughput equipment in Chile. We describe the implementation process and findings of the first 103 patients. They had heterogeneous phenotypes, including congenital anomalies, intellectual disabilities and/or immune system dysfunction. Patients underwent clinical exome or research exome sequencing, as solo cases or with parents using a trio design. We identified pathogenic, likely pathogenic or variants of unknown significance in genes related to the patients´ phenotypes in 47 (45.6%) of them. Half were de novo informative variants, and half of the identified variants have not been previously reported in public databases. DECIPHERD ended the diagnostic odyssey for many participants. This hybrid strategy may be useful for settings of similarly limited genomic resources and lead to discoveries in understudied populations.

7 June 2013 in Journal of Genetic Counseling
Verified
Journal Article
Open access
PDF file
SMSonia B. Margarit
Sonia B. Margarit
MAMónica Alvarado
Mónica Alvarado
KAKarin Alvarez
Karin Alvarez
GLGuillermo Lay-Son
Guillermo Lay-Son
In the South American Republic of Chile genetic counseling is not currently recognized as an independent clinical discipline, and in general is provided by physicians with training in clinical genetics. At present only one genetic counselor and 28 clinical geneticists practice in this country of over 16 million inhabitants. Pediatric dysmorphology constitutes the primary area of practice in clinical genetics. Although the country has a universal health care system and an adequate level of health care, genetic conditions are not considered a health care priority and there is a lack of clinical and laboratory resources designated for clinical genetics services. Multiple educational, cultural and financial barriers exist to the growth and development of genetic counseling services in Chile. However, during the last 10 years increased awareness of the importance of identifying individuals at risk for inherited cancer syndromes led to growing interest in the practice of cancer genetics.